GlassScriptPhysician profile
David H Oustecky
NPI 1952547945
$3,033.73
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $18.56 · 2022: $771 · 2023: $1,727 · 2024: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.75 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $789.27 | 2022-2024 | Xifaxan |
| Janssen Biotech, INC. | $243.96 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Merck Sharp & Dohme LLC | $238.14 | 2019-2024 | Dificid |
| Ardelyx, INC. | $173.33 | 2023-2024 | Ibsrela |
| Pfizer INC. | $125.71 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.40 | 2023-2024 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $91.72 | 2022-2023 | Zeposia |
| Capsovision, INC. | $75.65 | 2023 | Capsocam Plus |
| Redhill Biopharma INC. | $37.47 | 2023-2024 | Talicia |
| Lilly USA, LLC | $29.84 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $28.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.00 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $24.90 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.36 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.44 | 2022 | |
| Genzyme Corporation | $23.22 | 2024 | |
| Ferring Pharmaceuticals INC. | $22.82 | 2023 | Rebyota |
| Amgen INC. | $22.76 | 2023 | Amjevita |
| Nestle Healthcare Nutrition INC. | $22.40 | 2023 | |
| Fresenius Kabi USA, LLC | $20.83 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oustecky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.